JOHN CRADDOCK to Graft vs Host Disease
This is a "connection" page, showing publications JOHN CRADDOCK has written about Graft vs Host Disease.
Connection Strength
0.575
-
Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT. Transplant Cell Ther. 2026 Sep; 32(9):1051.e1-1051.e10.
Score: 0.163
-
Hematopoietic stem cell transplantation for B-thalassemia major with alemtuzumab. Pediatr Hematol Oncol. 2024 May; 41(4):260-272.
Score: 0.138
-
Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2024 02; 30(2):217-227.
Score: 0.137
-
Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children's Hospital experience. Bone Marrow Transplant. 2021 11; 56(11):2797-2803.
Score: 0.117
-
In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2173-2179.
Score: 0.019